Overview
SINOPHARM (1099)
Sinopharm Group Co. Ltd., together with its subsidiaries, engages in the wholesale and retail of pharmaceutical and healthcare products, and medical devices in...
- Open
- 16.780
- High
- 17.040
- Low
- 16.550
- Prev. Close
- 16.670
- Volume
- 4.11M
- Turnover
- 69.54M
- Avg Price
- 16.915
- Bid/Ask Ratio
- -79.17%
- Amplitude
- 2.94%
- 52wk High
- 21.550
- Volume Ratio
- 0.82
- Turnover Ratio
- 0.31%
- 52wk Low
- 14.550
- HK Mkt Cap
- 22.76B
- Market CapHKD
- 52.93B
- P/ETTM
- 6.34
- P/EDynamic
- 6.41
- P/EStatic
- --
- EPSTTM
- 2.67
- EPSDynamic
- 2.64
- EPSStatic
- --
- BVPS
- 32.57
- P/B
- 0.52
- HK Shares
- 1.34B
- Dividend YieldTTM
- 4.66%
- DividendTTM
- 0.79
- Shares
- 3.12B
- Min lot size
- 400
- Currency
- HKD
SINOPHARM Analyst Rating
View moreForecast & Rating
Oct 30, 2026- Strong buy38.46%
- Buy23.08%
- Hold38.46%
- Sell0.00%
- Strong sell0.00%
- Strong buy
- 5
- Buy
- 3
- Hold
- 5
- Sell
- 0
- Strong sell
- 0
Daily Events
- Nov, 16
Sinopharm closed up 1.74% at HKD16.96, driven by positive momentum from recent operational progress and compelling valuations. Morning session peaked at HKD16.99 before afternoon recovery to intraday highs near HKD17.03, with steady turnover. Key near-term catalysts include the company's newly signed three-year supply purchase agreement with CNPGC and Citi's upward target price revision to HKD20.5, published shortly after Q3 nine-month net profit slightly exceeded consensus. From a valuation standpoint, the stock trades at extremely compressed multiples—P/E of 6.34 and P/B of 0.52—while sitting above both the 20-day moving average (16.364) and 60-day moving average (15.677), suggesting technical support. Yet structural challenges remain: the stock has fallen 14.04% year-to-date and sits 24.08% below its 52-week peak of HKD22.34 (February 24), requiring substantial recovery. Recent disclosures of unpaid debt at a subsidiary further underscore operational headwinds.
- Nov, 13
Sinopharm Group (1099.HK) slipped 0.42% to HKD 16.67 today, oscillating between intraday low of 16.51 and high of 16.70. The recent Q3 earnings release has become a focal point, with revenues of HKD 169.43 billion rising 6.58% year-over-year and net profit of HKD 2.235 billion surging 11.04%, while EPS reached HKD 3.6781, up 2.36% year-over-year. Citi raised its target price to HKD 20.5, citing Q3 results slightly exceeded expectations. The company also just signed a three-year supply purchase agreement with CNPGC, and most brokers maintain buy ratings. However, the stock remains off its 52-week high of HKD 22.34 by 25.38%, having dropped 15.51% year-to-date, though its P/E of 6.24x, P/B of 0.51x, and dividend yield of 4.74% suggest attractive valuations. Meanwhile, Morgan Stanley noted that China's domestic pharmaceutical industry faces ongoing structural pressures, which could constrain future profit growth momentum.
- Nov, 12
Sinopharm slipped 0.12% to HKD 16.74, after climbing to HKD 16.87 during the morning session before afternoon profit-taking pulled it down. Q3 operating revenue reached RMB 1.694 trillion, up 6.58% year-over-year, with net profit of RMB 22.35 billion rising 11.04% YoY, demonstrating solid fundamentals. Analyst sentiment remains supportive: Citi recently raised its price target to HKD 20.5, and most brokers maintain buy ratings. Valuation appears attractive with PE of just 6.26x and PB of 0.51x, complemented by annual dividends of HKD 4.72. The stock is down 15.15% year-to-date and trades 25.07% below its 52-week high of HKD 22.34, suggesting a relative discount. However, the net profit margin contracted to 1.32% in Q3 from 1.40% in Q2, indicating ongoing industry headwinds.
- Nov, 11
Sinopharm (1099.HK) edged down 1.70% to 16.760 HKD, pressured by profit-taking after a rally. Morning trading opened at 17.010 and touched 17.070, but afternoon weakness took over, dropping to a low of 16.730 before closing at 16.760. Fundamentals remain constructive: a three-year supply agreement signed in early November; 3Q revenue of 169.4B HKD (+6.58% YoY) with net profit of 2.23B HKD (+11.04% YoY); Citi upgraded its target to 20.5 HKD. However, the stock is down 15.05% YTD and off 24.98% from February's 52-week high of 22.34 HKD. Trading at a thin PE of 6.27 and PB of 0.51, the stock reflects depressed pharmaceutical sector sentiment.
- Nov, 10
Sinopharm declined 0.58% to HKD17.05 after intraday volatility spanning morning and afternoon sessions. In the morning session, the stock peaked at HKD17.24 around 09:45 before consolidating higher to HKD17.13 by 11:59; the afternoon session opened at HKD17.15 at 13:00, then softened throughout the day, reaching a low of HKD17.04 at 15:58 before closing at HKD17.05. The decline primarily reflects profit-taking following earlier strength. However, recent developments offer multiple encouraging signals: Citi upgraded its target price to HKD20.5 (representing over 16% upside from current levels), with Q3 quarterly results showing sequential margin improvement; the company signed a three-year supply agreement with CNPGC, expanding strategic partnerships; consensus among research houses leans toward buy ratings. Valuations remain deeply attractive at historical lows, with a PE of just 6.38 and price-to-book ratio of 0.52, further supported by a compelling 4.63% dividend yield. Conversely, Morgan Stanley's recent commentary flagged persistent headwinds in China's domestic pharmaceutical sector, which could pressure near-term earnings growth momentum.
News
Weekly Review · Weekly Recap | SINOPHARM -2.8%, most brokers rate it buy
PUBT · Sinopharm Group Signs Three-Year Supply Purchase Agreement With CNPGC
Weekly Review · Weekly Recap | SINOPHARM this week, most brokers rate it buy
AASTOCKS News · Citi Slightly Raises SINOPHARM TP to HKD20.5, 3Q Net Profit Slightly Beats Forecast
AASTOCKS News · HSI Opens Up 48 Pts as LENOVO GROUP Rebounds 5%; Chip, AI Large Model Stocks Recover
Simplywall · Do Steady Q3 Earnings Change The Bull Case For Sinopharm Group (SEHK:1099)?
